TYK Medicines, Inc
Research TYK Medicines, Inc (2410.HK) on Bullrun: market cap HKD 1.22B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2410.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 1.22B
- Financial periodFY2025
- RevenueCNY 0
- Revenue growth-100.0%
- Net income-CNY 299.77M
- Free cash flow-CNY 255.18M
Valuation Snapshot
latest market cap is HKD 1.22B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 0 | -CNY 299.77M | -CNY 255.18M | n/a | n/a | CNY 316.49M | CNY 152.81M | CNY 286.67M |
| FY2024 | CNY 107.00K | -CNY 386.96M | -CNY 381.87M | 13.1% | -1.15 | CNY 435.46M | CNY 176.85M | CNY 469.09M |
| FY2023 | CNY 0 | -CNY 382.43M | -CNY 278.20M | n/a | -1.03 | CNY 186.83M | CNY 41.73M | -CNY 884.48M |
| FY2022 | CNY 44.24M | -CNY 310.99M | -CNY 308.23M | 45.3% | -0.84 | CNY 90.76M | CNY 55.95M | -CNY 505.94M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 1.22B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About TYK Medicines, Inc
TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation.
ETFs that hold TYK Medicines, Inc
US-listed ETFs
TYK Medicines, Inc is held by 2 US-listed ETFs, going by the latest portfolios they filed with the SEC, most traded first:
| ETF | Weight | Fee |
|---|---|---|
| State Street SPDR S&P China ETF (GXC) | <0.01% | 0.59% |
| State Street SPDR S&P Emerging Markets Small Cap ETF (EWX) | 0.01% | 0.65% |
Portfolios as filed with the SEC on Form N-PORT, dated June 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is TYK Medicines, Inc's market cap?
TYK Medicines, Inc's market capitalization is HKD 1.22B.
What does TYK Medicines, Inc do?
TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation.